Evommune EVMN
NYSE EVMN
$6.88 -0.31 (-4.31%)
At close: Oct 2, 2026 · 4:00 PM EDT

Evommune (EVMN) Change in Accured Expenses (2024 - 2026)

Updated

Evommune (EVMN) recorded Change in Accured Expenses of $5.95 million in Q2 2026, up 361.9% from $1.29 million a year earlier.

Analysis

Evommune (EVMN) Change in Accured Expenses (2024 - 2026) Analysis & Trends

On a TTM basis, Evommune's Change in Accured Expenses came in at $4.77 million as of Jun 30, 2026; for FY2025, it came in at $2.82 million, up 4.2% from FY2024.

  • Across earlier years, Change in Accured Expenses came in at $2.7 million in FY2024.
  • Per Business Quant, the preceding three quarters came in at -$4.81 million (Q1 2026), $4.3 million (Q4 2025) and -$666,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Accured Exp. (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn -
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 2.96 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 1.20 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn -251.00 Mn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn -
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 901.00 Mn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn 338.00 Mn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -
10 Evommune 260.87 Mn -376.65 Mn - 5.95 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.95 Mn
Mar 31, 2026 -4.81 Mn
Dec 31, 2025 4.30 Mn
Sep 30, 2025 -666,000.00
Jun 30, 2025 1.29 Mn
Mar 31, 2025 -2.10 Mn
Dec 31, 2024 -140,000.00
API Access

Evommune Change in Accured Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=EVMN&period=max&api_key=YOUR_API_KEY